Genentech Endowment for Cystic Fibrosis Genentech is committed to patients having access to all of our drugs for approved indications, including Pulmozyme® (dornase alfa). This commitment led Genentech to create the Genentech Endowment for Cystic Fibrosis. For eligible patients who are treated in the United States, Genentech will provide product to those who cannot afford to pay because we believe it is the right thing to do. The Endowment is funded by Genentech but operated through an independent board of directors with management by an outside firm. To learn more about the Endowment and about eligibility requirements, visit the Genentech Endowment for Cystic Fibrosis website or contact:

Genentech Endowment for Cystic Fibrosis
P.O. Box 222157
Charlotte, NC 28222-2157
(800) 297-5557